Explore evidence

3.6 aORHIV infection was associated with non-Hodgkin lymphoma (aOR 3.6 [CI 1.9-6.8]).

Côte d'Ivoirenon-Hodgkin lymphoma · VIH/sidapublished 2015Cancer epidemiologyeurope_pmcdocument of 7 observations

2.9 log10_copies_per_million_PBMCAt baseline, the median HIV-1 DNA was 2.9 log10 copies/million PBMC [IQR 2.5–3.3] in HIV-infected adults in the Temprano trial.

Côte d'IvoireVIH/sidapublished 2020EBioMedicineeurope_pmcdocument of 7 observations

34.6 aORHIV infection was associated with Kaposi sarcoma (aOR 34.6 [CI: 17.3-69.0]).

Côte d'Ivoiresarcome de Kaposi · VIH/sidapublished 2015Cancer epidemiologyeurope_pmcdocument of 7 observations

3.1 %HIV prevalence was 3.1% among inmates screened at the Correctional and Detention Facility of Abidjan.

Côte d'IvoireVIH/sidaobserved 2015published 2017PloS oneeurope_pmcdocument of 8 observations

16.69 yearsDiscounted life expectancy was 16.69 years for the standard of care (biannual CD4 monitoring).

Côte d'IvoireVIH/sidapublished 2016Clinical infectious diseases : an official publication of the Infectious Diseases Society europe_pmcdocument of 5 observations

97 %Type-1 HIV was found in 97% of 491 adult HIV patients.

Côte d'IvoireVIH/sidaobserved 2006published 2012World journal of hepatologyeurope_pmcdocument of 13 observations

6 %Among hospitalized HIV-positive adults in West Africa, non-specific illness was the underlying cause of hospitalization in 6% of patients.

Côte d'IvoireVIH/sidaobserved 2010published 2014Journal of the International AIDS Societyeurope_pmcdocument of 22 observationsDOI 10.7448/ias.17.1.18797

72.9 %Anti-HBcAb prevalence was 72.9% among 491 adult HIV patients in Abidjan.

Côte d'Ivoirehépatite B · VIH/sidaobserved 2006published 2012World journal of hepatologyeurope_pmcdocument of 13 observations

18 casesOf the 1023 HIV-1-infected adults randomized in the Temprano deferred-ART group, 18 (1.8%) met the criteria for classification as HIV controllers.

Côte d'IvoireVIH/sidapublished 2022AIDS (London, England)europe_pmcdocument of 3 observations

2.6 %The HIV prevalence rate is 2.6% in Ivory Coast.

Côte d'IvoireVIH/sidaHAL · Unilimdocument of 97 observations

0.86 probabilityThe 36-month probability of immunovirologic success was 0.86 in patients with a medication possession ratio (MPR) of 90% or higher.

Côte d'IvoireVIH/sidapublished 2009AIDS research and human retroviruseseurope_pmcdocument of 2 observations

5.2 aORHIV infection was associated with squamous cell skin carcinoma (aOR 5.2 [CI 2.0-14.4]).

Côte d'Ivoiresquamous cell skin carcinoma · VIH/sidapublished 2015Cancer epidemiologyeurope_pmcdocument of 7 observations

74 %74% of HIV-2-treated patients in Côte d'Ivoire displayed viral load less than 50 copies/ml.

Côte d'IvoireVIH/sidapublished 2014AIDS (London, England)europe_pmcdocument of 9 observations

Three men aged 33, 44, and 45 years were admitted for hip pain and impaired mobility.

Côte d'Ivoireavascular osteonecrosis of the femoral head · VIH/sidapublished 2009Antiviral therapyeurope_pmcdocument of 11 observations

54 %Among hospitalized HIV-positive adults in West Africa, AIDS-defining conditions were the underlying cause of hospitalization in 54% of patients.

Côte d'IvoireVIH/sidaobserved 2010published 2014Journal of the International AIDS Societyeurope_pmcdocument of 22 observationsDOI 10.7448/ias.17.1.18797

22 monthsThe mean time on highly active antiretroviral therapy (HAART) was 22 months among HIV-infected adults in Abidjan.

Côte d'IvoireVIH/sidapublished 2007Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument of 2 observationsDOI 10.1097/qai.0b013e31805d8ad0

43 yearsThe average age of the 36 HIV-infected patients was 43±12 years.

Côte d'IvoireVIH/sidaobserved January 2005-July 2015published 2018The Pan African medical journaleurope_pmcdocument of 9 observations

2.3 per_100_person-yearsThe incidence of death among HIV-infected adults receiving antiretroviral treatment was 2.3 per 100 person-years.

Côte d'IvoireVIH/sidapublished 2013BMC infectious diseaseseurope_pmcdocument of 10 observationsDOI 10.1186/1471-2334-13-607

65 %CRF02 (>65%) cocirculates with other HIV-1 variants in Senegal and Côte d'Ivoire.

Côte d'Ivoire · SénégalVIH/sidapublished 2009AIDS Research and Human RetrovirusesOpenAlexdocument of 3 observations

2 per_person_yearMortality among people living with HIV/AIDS during the first year of antiretroviral therapy implementation was 2–3% per person-year.

Côte d'IvoireVIH/sidapublished 2009Medecine tropicale : revue du Corps de sante colonialeurope_pmcdocument of 5 observations

19 %At month 24 after ART initiation, 19% of patients in active follow-up had virus resistant to at least one antiretroviral drug.

Côte d'IvoireVIH/sidapublished 2013Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument of 11 observations

24.4 %Hospital mortality among hospitalized HIV-infected patients was 24.4%.

Côte d'IvoireVIH/sidapublished 2013Bulletin de la Societe de pathologie exotique (1990)europe_pmcdocument of 16 observations

376 USD_per_DALY_averterdThe incremental cost-effectiveness ratio when comparing the resistance test policy with the no switch policy was $376 per DALY averted.

Côte d'IvoireVIH/sidapublished 2025The lancet. HIVeurope_pmcdocument of 6 observations

48 patientsDuring 34 months of follow-up, 48 patients (77.4%) received first-line treatment.

Côte d'IvoireVIH/sidaobserved 34 monthspublished 2010Le Mali medicaleurope_pmcdocument of 17 observations

9 %Among hospitalized HIV-positive adults in West Africa who died, cryptococcosis was a fatal disease in 9% of deaths.

Côte d'Ivoirecryptococcosis · VIH/sidaobserved 2010published 2014Journal of the International AIDS Societyeurope_pmcdocument of 22 observationsDOI 10.7448/ias.17.1.18797